Liquidia said the dispute concerns its YUTREPIA product and a United Therapeutics patent. The filing gives no court ruling or product-access change, so it does not show a change in Liquidia's outlook.
The case involves Liquidia's lead product, so its outcome could matter to the company. This filing gives no court decision, claim details, or stated change to product access. It therefore does not show a change in Liquidia's prospects.
United Therapeutics is identified as the company that filed the case over its patent and Liquidia's YUTREPIA. The filing gives no court ruling or case outcome, so it does not show a change in United Therapeutics' outlook.
Follow Liquidia Corp (LQDA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for LQDA